Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHRQ Considers Academic Detailing To Distribute CER Findings

Executive Summary

The Agency for Healthcare Research and Quality is considering "academic detailing" as a means of disseminating comparative effectiveness research findings to health care providers and recently took steps to gauge interest in such a program

You may also be interested in...



Taking CER To The Doctor: AHRQ Academic Detailing Project Gets Under Way

When first introduced as a funding opportunity for some of the $1.1 billion put aside for comparative effectiveness research under the American Recovery and Reinvestment Act, using academic detailing as a way to disseminate CER findings raised some eyebrows.

Taking CER To The Doctor: AHRQ Academic Detailing Project Gets Under Way

When first introduced as a funding opportunity for some of the $1.1 billion put aside for comparative effectiveness research under the American Recovery and Reinvestment Act, using academic detailing as a way to disseminate CER findings raised some eyebrows.

Retooling The Sales Force Remains A Work In Progress

Pharmaceutical sales reps may not relish the thought, but they could play leading roles in a Hollywood epic called 'The Incredible Shrinking Sales Force.' Between 2005 and the third quarter of 2009, the number of reps industry wide in the U.S. fell from 101,818 to 81,780, a 19.7 percent decline, according to SDI Health

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel